DGAP-News: Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

"Patients in the EMPhASIS trial exhibited robust responses across all study endpoints included in the top-line analysis.